Merck & Co., Inc. (BCBA:MRK)

Market Cap	347.45T
Revenue (ttm)	88.03T
Net Income (ttm)	26.09T
Shares Out	n/a
EPS (ttm)	10,355.40
PE Ratio	13.32
Forward PE	10.89
Dividend	493.24 (1.69%)
Ex-Dividend Date	Sep 15, 2025

Volume	3,006
Average Volume	5,345
Open	30,200
Previous Close	30,280
Day's Range	28,880 - 30,200
52-Week Range	16,950 - 32,380
Beta	0.30
RSI	51.97
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD